Breaking Down Shilpa Medicare Limited Financial Health: Key Insights for Investors

Investors tracking Shilpa Medicare will want to dig into Q3 FY25 figures that show revenue from operations at ₹319.32 crore, up 11.35% year-on-year and part of a fiscal-year total of ₹1,286.41 crore (+11.71% YoY), while Q2 FY25 breakdowns reveal the API segment contributing 55% (₹192.8 crore), formulations 34% (₹119.6 crore) and biologics 9% (₹30.7 crore); profitability swung sharply with Q3 EBITDA rising 20% to ₹82 crore and EBITDA margin improving to 26%, net profit jumping to ₹31.78 crore in Q3 (a staggering 593.88% YoY surge) and FY25 PAT at ₹78.29 crore (+145.65%); balance-sheet moves include total liabilities of ₹3,297.74 crore, long-term debt cut by 58.6% to ₹2,320 crore from March 2024 and shareholder funds climbing 31.2% to ₹2,372.24 crore, while net debt fell to ~₹55,770 lakh from ₹90,386 lakh even as finance cost rose to ₹9,181 lakh and depreciation reached ₹10,787 lakh; cash flows show operating cash at ₹1,322 crore, investing at -₹1,991 crore and net cash flow at -₹32 crore, total assets up 7% to ₹3,297.74 crore and current liabilities down 2.8% to ₹6,742 crore; market moves include a year-to-date share price surge of 173%, a P/E of 170.20x and EPS ₹4.85 (consensus target ₹974), while analysts project revenues of ₹1,720 crore and EPS of ₹25.30 in 2026; risks range from a 41% miss on EPS estimates to sensitivity to raw material costs, FX swings and high valuation-driven volatility, and growth levers include ~25% YoY API growth, a 115% expansion in biologics, EU generic Nilotinib launch and NorUDCA approval.

Shilpa Medicare Limited (SHILPAMED.NS) - Revenue Analysis

Shilpa Medicare reported steady top-line growth across FY25 and sequential quarters, driven by finished dosage forms (FDF), APIs and a growing biologics portfolio. Key headline figures and segment mix are summarized below.

• Q3 FY25 revenue from operations: ₹319.32 crore, up 11.35% YoY.
• Full year FY25 total revenue: ₹1,286.41 crore, up 11.71% YoY.
• Q2 FY25 revenue from operations: ₹343.80 crore, up 9.85% YoY.
• Q2 FY25 segment mix: API 55% (₹192.8 crore), Formulations 34% (₹119.6 crore), Biologics 9% (₹30.7 crore).

Segment contribution details (Q2 FY25):

• APIs remain the backbone of revenue, contributing the majority share (55%) in Q2 FY25.
• Formulations/FDF provide diversification and strong margin potential at 34% of Q2 revenue.
• Biologics, while smaller at 9%, is a strategic growth area and is increasingly visible in quarter-on-quarter revenue mix.

For broader context on the company's strategy, ownership and evolution, see: Shilpa Medicare Limited: History, Ownership, Mission, How It Works & Makes Money

Shilpa Medicare Limited (SHILPAMED.NS) - Profitability Metrics

• Q3 FY25: EBITDA rose 20% YoY to ₹82.00 crore; EBITDA margin improved to 26% from 24% in Q3 FY24.
• Q3 FY25: Net profit (PAT) of ₹31.78 crore, up 593.88% from ₹4.58 crore in Q3 FY24.
• FY ending Mar 2025: Net profit increased 145.65% to ₹78.29 crore from ₹31.87 crore in FY24.
• Q2 FY25: EBITDA margin improved to 26% from 20% in Q2 FY24, indicating operational leverage.
• Q2 FY25: Profit before tax (PBT) surged 300.98% to ₹36.77 crore from ₹9.17 crore in Q2 FY24.
• Q2 FY25: PAT was ₹17.94 crore, up 1,042.68% from ₹1.60 crore in Q2 FY24.

• Margin expansion from 20-24% to 26% across recent quarters points to improved cost control and higher-margin product mix.
• Large YoY PAT jumps in Q2 and Q3 FY25 reflect both operational improvements and likely one-off or scale effects; investors should review accompanying notes for drivers.
• Consistent EBITDA margin at 26% in Q2 and Q3 FY25 suggests strengthening core profitability.

Shilpa Medicare Limited (SHILPAMED.NS) - Debt vs. Equity Structure

• Total liabilities (Mar 2025): ₹3,297.74 crore.
• Long-term debt (Mar 2025): ₹2,320 crore, down 58.6% from ₹5,602 crore in Mar 2024.
• Shareholder's funds (Mar 2025): ₹2,372.24 crore, up 31.2% from ₹1,808.69 crore in Mar 2024.
• Net debt: ~₹55,770 lakh in FY25 vs ₹90,386 lakh in FY24.
• Finance cost: ₹9,181 lakh in FY25 (up 57% from ₹5,865 lakh in FY24).
• Depreciation & amortization: ₹10,787 lakh in FY25 (up 13% YoY).

• Improved leverage: Lower long-term debt and higher equity reduce financial risk and improve solvency ratios (debt-to-equity, net-debt-to-EBITDA if calculated).
• Interest dynamics: Despite lower nominal debt, finance cost rose 57%-indicative of higher average borrowing costs, one-time charges, or short-term/structured financing replacing some long-term borrowings.
• Asset-charge trend: Higher depreciation/amortization suggests recent capex or revaluation impacting operating profit metrics and tax profiles.
• Liquidity & coverage focus: Material net-debt reduction (~₹34,616 lakh decline) signals active deleveraging but warrants review of cash flows and interest coverage given rising finance costs.

Shilpa Medicare Limited (SHILPAMED.NS) - Liquidity and Solvency

• Operating cash flow (FY25): ₹1,322 crore (down 3.3% from ₹1,367 crore in FY24)
• Investing cash flow (FY25): ₹-1,991 crore (improved 19.5% YoY)
• Financing cash flow (FY25): ₹627 crore (up 34% YoY)
• Net cash flow (FY25): ₹-32 crore (vs ₹127 crore in FY24)
• Total assets (Mar 2025): ₹3,297.74 crore (up 7% from ₹3,082.98 crore in Mar 2024)
• Current liabilities (Mar 2025): ₹6,742 crore (down 2.8% from ₹6,936 crore in Mar 2024)

• Improved investing cash flows indicate reduced investment outflows in FY25 versus FY24, helping limit further cash depletion.
• Reduction in current liabilities and growth in total assets suggest modest improvement in short-term financial posture despite a negative net cash flow in FY25.
• Operating cash flow remains the primary source of internal liquidity but shows slight erosion year-on-year; financing inflows partially offset investing outflows.

Shilpa Medicare Limited (SHILPAMED.NS) - Valuation Analysis

• Year-to-date stock performance: +173% vs. BSE Sensex: +7.7%.
• Current P/E multiple: 170.20x based on EPS of ₹4.85.
• Market capitalization: ₹8,556.70 crore (mid-cap pharmaceutical range).
• Consensus price target: ₹974, implying meaningful upside from the current trading price.

• Growth drivers priced in: Analysts expect revenue growth of ~34% to FY2026 and a substantial EPS expansion (c. +180%), which underpins the elevated P/E multiple.
• Valuation risk: A very high current P/E (170x) means downside sensitivity to any earnings shortfall or growth miss.
• Return potential: Consensus target of ₹974 indicates analyst confidence in re-rating driven by profit expansion; monitoring quarterly execution versus the revenue/EPS trajectory is critical.
• Contextual reference: For background on company strategy, ownership and business model, see Shilpa Medicare Limited: History, Ownership, Mission, How It Works & Makes Money.

Shilpa Medicare Limited (SHILPAMED.NS) - Risk Factors

• Earnings Volatility: The company missed earnings per share (EPS) estimates by 41% in its latest full-year results, a material shortfall that signals potential volatility in future earnings projections.
• Valuation Risk: A high trailing P/E ratio of 170.20x implies elevated market expectations. Any underperformance versus forecasts could trigger sharp downside price moves.
• Raw Material & Input-Cost Risk: Fluctuations in API and excipient prices can compress gross margins, especially for price-sensitive formulations and contract-manufacturing lines.
• Regulatory & Market Access Risk: Changes in regulatory requirements or slower approvals in key markets (domestic and exports) could delay product launches and revenue recognition.
• Short-term Finance-Cost Pressure: The company's ongoing debt reduction efforts may require increased short-term borrowing or higher finance costs during transition, which could temporarily depress net margins.
• Currency Risk: Revenue and cost exposure to multiple currencies means exchange-rate volatility can materially affect reported topline and margins.
• Competitive Pressure: Intense competition in generics, specialty formulations and contract manufacturing may pressure pricing, volumes and market share.

• Scenario Sensitivities investors should model:
  • EPS downside: Re-run valuations assuming 20-40% lower EPS than consensus given the recent 41% miss.
  • Margin compression: Test gross-margin declines of 200-500 bps from raw-material or pricing pressure.
  • Finance-cost spike: Incorporate a temporary 50-200 bps rise in net interest expense during active debt-reduction phases.
  • FX swing: Stress test ±5-10% currency moves on reported revenue and PAT based on export mix.

Shilpa Medicare Limited (SHILPAMED.NS) - Growth Opportunities

• API division: reported growth of approximately 25% year-on-year, reflecting resilient demand and capacity utilization gains.
• First generic of Nilotinib launched in the EU: opens new revenue streams and enhances presence in regulated markets.
• NorUDCA approval: positions Shilpa Medicare as a leader in NAFLD treatment with a differentiated product offering.
• Biologics expansion: segment grew by 115% in FY25, indicating rapid traction and scalable revenue potential.
• R&D and innovation focus: emphasis on complex generics and biosimilars supports long-term pipeline value and margin expansion.
• Strategic partnerships and global market expansion initiatives: expected to drive incremental revenue and market share in regulated and semi-regulated geographies.